Events

UPCOMING EVENTS

  • World CDx  |  September 4-6, Boston, MA (Spotlight Partner)
  • Spatial Biology in Drug Development |  October, Boston, MA (Program Partner)

CB&CDx – Sept 12, 2019

CB&CDx – Sept 12, 2019

ANALYTICAL ADVANCEMENTS TO POWER BIOMARKER DEVELOPMENT TRACK PRESENTATION: ADDING VALUE TO TRADITIONAL IN VITRO DIAGNOSTICS (IVDS) AT WORLD CB&CDXSeptember 12, 2019 at 2:50pm The Renaissance Boston Waterfront, Boston, MA Speaker: Kelsey Weigel, PhD, Scientist II,...

read more
CB&CDx – Sept 12, 2019

CB&CDx – Sept. 9-12, 2019

WORLD CB AND CDX BOSTON 2019 (CLINICAL BIOMARKER AND COMPANION DIAGNOSTICS)September 9-12, 2019 The Renaissance Boston Waterfront, Boston, MA Flagship Biosciences is a proud Spotlight Partner of World CB and CDx Boston 2019. Flagship’s leaders will be speaking and...

read more

Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.

Recent Posts

NEWS

Flagship Biosciences Announces Strategic Executive Team Additions

Dr. Roberto Gianani and Michael Koratich Named to Key Medical and Pharma RolesWestminster, CO – March 10, 2021 – Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced strategic additions to its executive team. Dr. Roberto...

Flagship Biosciences Announces Patent

Patent Number 10,839,512 Issued for New Tissue Sample Image Dot Detection MethodWestminster, CO – February 17, 2021 – Flagship Biosciences, the leader in data-centric pathology tissue analysis, today announced that the United States Patent and Trademark Office has...

PUBLICATIONS/POSTERS

CIOReview Names Flagship Company of the Year

CIOReview named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful solution is yet another massive...

Using Artificial Intelligence to Predict Response to Immunotherapy

Key Concepts: Pathological interpretations applied to PD-L1 IHC as a response biomarker are becoming more complex, going beyond simple tumor proportion score (TPS) and requiring more complex diagnostic algorithms that evaluate the role of PDL1 expression in tumor...

Pathology AI (Artificial Intelligence)

Key takeways:  Successful pathology AI does not replace, but assist pathologists in high-complexity tissue analysis Transparency and control is retained in a pathologist-centric AI-based system Pathology AI enables cost effective healthcare by testing for multiple...